LPL Financial LLC Acquires 5,500 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV)

LPL Financial LLC increased its stake in Achieve Life Sciences, Inc. (NASDAQ:ACHV) by 2.9% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 196,833 shares of the biopharmaceutical company’s stock after buying an additional 5,500 shares during the period. LPL Financial LLC’s holdings in Achieve Life Sciences were worth $693,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in ACHV. Sigma Planning Corp bought a new stake in Achieve Life Sciences in the fourth quarter worth about $37,000. SBI Securities Co. Ltd. purchased a new stake in shares of Achieve Life Sciences during the 4th quarter worth approximately $49,000. Intech Investment Management LLC bought a new stake in shares of Achieve Life Sciences in the 4th quarter worth approximately $58,000. SG Americas Securities LLC lifted its stake in Achieve Life Sciences by 74.8% in the fourth quarter. SG Americas Securities LLC now owns 19,886 shares of the biopharmaceutical company’s stock valued at $70,000 after purchasing an additional 8,512 shares during the last quarter. Finally, Barclays PLC lifted its stake in Achieve Life Sciences by 303.1% in the third quarter. Barclays PLC now owns 47,655 shares of the biopharmaceutical company’s stock valued at $226,000 after purchasing an additional 35,832 shares during the last quarter. Institutional investors own 33.52% of the company’s stock.

Insider Activity

In related news, CFO Mark K. Oki purchased 10,000 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was purchased at an average cost of $2.89 per share, with a total value of $28,900.00. Following the completion of the acquisition, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at approximately $28,900. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 2.00% of the company’s stock.

Achieve Life Sciences Stock Performance

NASDAQ:ACHV opened at $2.48 on Wednesday. The company has a market capitalization of $86.02 million, a P/E ratio of -2.19 and a beta of 1.59. The business has a fifty day simple moving average of $2.69 and a two-hundred day simple moving average of $3.60. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.78 and a quick ratio of 6.78. Achieve Life Sciences, Inc. has a 1 year low of $1.84 and a 1 year high of $5.59.

Achieve Life Sciences (NASDAQ:ACHV) last announced its quarterly earnings data on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.06). On average, analysts expect that Achieve Life Sciences, Inc. will post -1.17 earnings per share for the current year.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.